Gastric cancer patients with acute disseminated intravascular coagulation experiences a rare but severe complication resulting in a dismal prognosis. We report a case of advanced gastric cancer complicated with disseminated intravascular coagulation with intractable tumor bleeding which was successfully treated with chemotherapy consisting of 5-fluorouracil and oxaliplatin. The patient was a 63-yearold man who complained of abdominal pain, melena, and dyspnea on 24 November 2010. We diagnosed stage IV gastric cancer complicated by disseminated intravascular coagulation. Gastric tumor bleeding was not controlled after procedures were repeated three times using gastrofiberscopy. With the patient's consent, we selected the 5-fluorouracil and oxaliplatin combination chemotherapy for treatment. After one cycle of 5-fluorouracil and oxaliplatin therapy, symptoms of bleeding improved and the disseminated intravascular coagulation process was successfully controlled. The primary tumor and multiple metastatic bone lesions were remarkably shrunken and metabolically remitted after eight cycles of chemotherapy. In spite of progression, systemic chemotherapy is effective in disease control; further, the patient gained the longest survival time among cases of gastric cancer with disseminated intravascular coagulation.
Introduction
Gastric cancer is the fifth most common malignant tumor and ranks second for cancer deaths worldwide.
1 Disseminated intravascular coagulation (DIC) is a pathologic syndrome in which the manifestations, such as progressive and consumptive coagulopathy with severe bleeding, are in large part a consequence of thrombin formation. 2 Solid tumors such as gastrointestinal, pancreatic, liver, ovarian, breast, lung and prostatic carcinomas can induce acute DIC complication. 3 The gastric cancer patient with acute DIC experiences a rare but severe complication resulting in a very dismal prognosis. DIC associated with gastric adenocarcinoma occurs through the exacerbation of the blood clotting process by which procoagulant materials such as mucin extracts derived from tumor cells directly stimulate coagulation factor X or damage red blood cells and platelets by direct contact with tumor cells on microvessel.
Active tumor treatment improves DIC, rather than palliative treatments such as coagulation factor and platelet transfusions. Choosing the appropriate chemotherapy agents to treat the underlying cancer and stop the acute DIC process effectively, while avoiding chemotherapy induced myelosuppresion which may contribute to bleeding related mortality, is difficult. However, many clinicians tend to be reluctant to apply palliative chemotherapy due to potent adverse events combined with intrinsic hematologic fragility. Because we experienced a case of proven metabolic complete remission in which chemotherapy significantly improved the gastric cancer and thereby the accompanying DIC, we report this case.
Case Report
The 63-year-old man was admitted to the hospital on 24 November 2010 with epigastric pain, diffuse back pain and melena. Because there was bleeding on a vessel exposed to the area of mass, argon plasma coagulation was performed (Fig. 1A) . Endoscopic biopsy results were poorly differentiated adenocarcinoma.
Abdominal computed tomography scanning revealed gastric cancer in the lower body and multiple metastases in neighboring lymph nodes, and abdominal lymph nodes were observed. Liver and bi- He felt better than before chemotherapy, melena stopped and the petechiae of lower extremities disappeared. His back pain, previously uncontrolled by high dose opioid administration, dramatically improved after chemotherapy.
Chemotherapy was treated 6 times in a total of 6 months.
Traced abdominal computed tomography scanning, positron emission tomography scanning and upper gastrointestinal endoscopy (Fig. 1B) showed complete remission of gastric cancer, lymph nodes and metastases areas (Fig. 2B) . (Fig. 2D ). But after 6 cycles of second line chemotherapy, PET-CT scan showed that multiple bone metastases and both adrenal metastases were aggravated (Fig. 2E) . We performed In metastatic gastric cancer, combination chemotherapy has been primarily used 10, 11 and the most commonly used drugs are cisplatin and 5-FU. 10 In this case, hematologic complications were not controlled by conservative treatment including repeated endoscopic bleeding control and RBC, platelet and frozen fresh plasma This case showed that combination administration of oxaliplatin, leucovorin and 5-FU improved DIC and produced clinically complete remission in case of DIC, liver metastasis, bone metastasis and aortic lymph node metastasis. To our knowledge, this patient is the longest survivor whose initial presentation was metastatic gastric cancer combined with DIC, with survival at more 22 months.
Most reported cases ultimately died of disease progression and re-developed DIC. 15 In this case, the event provoking DIC was tumor bleeding. We should consider more aggressive treatment for underlying disease to stop the vicious cycle of bleeding and consumptive DIC, because we can predict more favorable outcome DIC provoked with tumor bleeding. This is only one case report, but our report suggests that early and intensive management for DIC and systemic chemotherapy improves prognosis in this clinical setting.
This case suggests that more effective and less toxic regimens are needed.
In general, performance status and organ functions are most important factor when consider palliative chemotherapy in metastatic cancer patients for safety and tolerability. This case was not satisfied the performance status but, showed that systemic chemotherapy could control the tumor bleeding control and the complication of DIC, and eventually prolongs survival beyond prediction. Therefore, early and intensive management for correctable DIC followed by systemic chemotherapy should be considered in patients with DIC like this patient. There are several equivalent of combination of first line chemotherapy in case of advanced gastric cancer, among them; 5-FU and oxaliplatin combination could be a safe and effective chemotherapy option in DIC complicated gastric cancer patients because of the rapid, effective tumor response which was induced with rapid control of the DIC. Therefore, early and intensive management for correctable DIC followed by chemotherapy should be considered for patients with gastric cancer who initially present with DIC for improving prognosis.
